Establishment and application of a high-throughput drug screening model based on COL1A1 promoter for anti-liver fibrosis

Yaoxue Xuebao

Volumn 50, Issue 2, 2015, Pages 169-173

  Zhao, Shuang Shuang ^a   Wang, Ju Xian ^a   Wang, Yu Cheng ^a   Shao, Rong Guang ^a   He, Hong Wei ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Cell model; High throughput drug screening; Liver fibrosis; Luciferase reporter gene

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; COLLAGEN TYPE I, ALPHA 1 CHAIN; LUCIFERASE;

ARTICLE; CELL CULTURE; COL1A1 PROMOTER; CONTROLLED STUDY; DRUG INHIBITION; FLUORESCENCE; GENE ACTIVITY; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; PLASMID; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SIGNAL TRANSDUCTION; STABLE EXPRESSION; STABLE TRANSFECTION; STELLATE CELL; WESTERN BLOTTING; GENETICS; LIVER CIRRHOSIS; PRECLINICAL STUDY; PROCEDURES;

COLLAGEN TYPE I; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; HEPATIC STELLATE CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIVER CIRRHOSIS; LUCIFERASES; PLASMIDS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84924631021     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis [J]. J Gastroenterol Hepatol, 2007, 22:S73-S78.
2. Guo J, Friedman SL. Hepatic fibrogenesis [J]. Semin Liver Dis, 2007, 27:413-426.
3. Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis [J]. J Gastroenterol Hepatol, 2006, 21:S84-S87.
4. Friedman SL. Hepatic fibrosis - overview [J]. Toxicology. 2008, 254:120-129.
5. Shek FW, Benyon RC. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? [J]. Eur J Gastroenterol Hepatol, 2004, 16:123-126.
6. Traber PG, Chou H, Zomer E, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease [J]. PLoS One, 2013, 8:e75361.
7. Fallowfield JA, Iredale JP. Reversal of liver fibrosis and cirrhosis - an emerging reality [J]. Scott Med J, 2004, 49:3-6.
8. Giannone FA, Baldassarre M, Domenicali M, et al. Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl (4)-induced advanced cirrhosis [J]. Lab Invest, 2012, 92:384-395.
9. Fallowfield J, Hayes P. Pathogenesis and treatment of hepatic fibrosis: is cirrhosis reversible? [J]. Clin Med, 2011, 11:179-183.
10. Zhao SS, Shao RG, He H. Potential targets for anti-liver fibrosis [J]. Acta Pharm Sin, 2014, 49:1365-1371.
11. Bataller R, Brenner DA. Liver fibrosis [J]. J Clin Invest, 2005, 115:209-218.
12. Stefanovic B, Stefanovic L. Screening for antifibrotic compounds using high throughput system based on fluorescence polarization [J]. Biology, 2014, 3:281-294.
13. He H, Mennone A, Boyer JL, et al. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells [J]. Hepatology, 2011, 53:548-557.